186 related articles for article (PubMed ID: 15728367)
1. Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.
Rekasi Z; Czompoly T; Schally AV; Boldizsar F; Varga JL; Zarandi M; Berki T; Horvath RA; Nemeth P
Proc Natl Acad Sci U S A; 2005 Mar; 102(9):3435-40. PubMed ID: 15728367
[TBL] [Abstract][Full Text] [Related]
2. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
3. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
Letsch M; Schally AV; Busto R; Bajo AM; Varga JL
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1250-5. PubMed ID: 12538852
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
[TBL] [Abstract][Full Text] [Related]
6. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.
Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
Oncotarget; 2016 Aug; 7(32):52195-52206. PubMed ID: 27448980
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.
Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Prieto JC; Bajo AM
Invest New Drugs; 2014 Oct; 32(5):871-82. PubMed ID: 25000999
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
Plonowski A; Schally AV; Varga JL; Rekasi Z; Hebert F; Halmos G; Groot K
Prostate; 2000 Jul; 44(2):172-80. PubMed ID: 10881027
[TBL] [Abstract][Full Text] [Related]
11. The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation.
Garcia-Fernandez MO; Schally AV; Varga JL; Groot K; Busto R
Breast Cancer Res Treat; 2003 Jan; 77(1):15-26. PubMed ID: 12602901
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways.
Rekasi Z; Varga JL; Schally AV; Plonowski A; Halmos G; Csernus B; Armatis P; Groot K
Peptides; 2001 Jun; 22(6):879-86. PubMed ID: 11390017
[TBL] [Abstract][Full Text] [Related]
13. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas.
Busto R; Schally AV; Varga JL; Garcia-Fernandez MO; Groot K; Armatis P; Szepeshazi K
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11866-71. PubMed ID: 12186980
[TBL] [Abstract][Full Text] [Related]
14. The growth hormone-releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line.
Annunziata M; Grande C; Scarlatti F; Deltetto F; Delpiano E; Camanni M; Ghigo E; Granata R
Fertil Steril; 2010 Aug; 94(3):841-9. PubMed ID: 19524226
[TBL] [Abstract][Full Text] [Related]
15. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.
Halmos G; Schally AV; Czompoly T; Krupa M; Varga JL; Rekasi Z
J Clin Endocrinol Metab; 2002 Oct; 87(10):4707-14. PubMed ID: 12364462
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart.
Granata R; Trovato L; Gallo MP; Destefanis S; Settanni F; Scarlatti F; Brero A; Ramella R; Volante M; Isgaard J; Levi R; Papotti M; Alloatti G; Ghigo E
Cardiovasc Res; 2009 Jul; 83(2):303-12. PubMed ID: 19293247
[TBL] [Abstract][Full Text] [Related]
17. Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers.
Plonowski A; Schally AV; Busto R; Krupa M; Varga JL; Halmos G
Peptides; 2002 Jun; 23(6):1127-33. PubMed ID: 12126741
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of a second generation growth hormone-releasing peptide (Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2) in rat anterior pituitary cells.
Akman MS; Girard M; O'Brien LF; Ho AK; Chik CL
Endocrinology; 1993 Mar; 132(3):1286-91. PubMed ID: 8095015
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line.
Barabutis N; Schally AV
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20470-5. PubMed ID: 19075233
[TBL] [Abstract][Full Text] [Related]
20. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
